BDX: Becton, Dickinson and Company - Summary | Jitta

Becton, Dickinson and Company

NYSE:BDX

Price
$252.38
Loss Chance
46.0%
4.51JITTA SCORE
19.39%Over Jitta Line
Jitta Ranking
106 / 1,197
1,467 / 5,062
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (23)
Recent Business Performance (13)
Financial Strength (71)
Return to Shareholders (51)
Competitive Advantage (34)
Jitta Signs
Dividend PayoutIncreasing Every Year
Interest Coverage RatioVery Good
Revenue and EarningEarning decline from 2019-2022
Recent Business PerformanceEarning decline 10.04% in the last year
Key Stats
Jitta Score
Jitta Line
4.51
19.39%
2.00
242.70%
Health Care Equipment
5.45
182.17%
6.90
110.97%
6.13
12.54%
COMPANY DESCRIPTION
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.